Physician profile
Charla Sperring
NPI 1871940965
$4,388.93
in general payments reported to CMS, 2019-2025
42 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.03 · 2020: $108 · 2021: $100 · 2022: $585 · 2023: $784 · 2024: $1,647 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,570.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.95 | 2020-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $434.79 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $341.75 | 2023-2025 | |
| Lilly USA, LLC | $269.60 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $255.24 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.89 | 2023-2025 | Jardiance, Ofev |
| Corium, LLC | $225.27 | 2024-2025 | Azstarys |
| Amgen INC. | $192.53 | 2022-2025 | Evenity, Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $158.09 | 2022 | |
| Lundbeck LLC | $146.47 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $143.52 | 2020-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $140.18 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.05 | 2022-2025 | Xifaxan |
| Dexcom, INC. | $127.80 | 2023-2025 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $124.98 | 2024-2025 | Fanapt |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $109.92 | 2023-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $107.47 | 2023-2024 | Jornay Pm |
| Exact Sciences Corporation | $99.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aimmune Therapeutics, INC. | $67.10 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.51 | 2019-2025 | |
| Shield Therapeutics INC | $53.97 | 2023-2024 | Accrufer |
| Ascensia Diabetes Care US INC. | $46.33 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $44.74 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Ardelyx, INC. | $41.32 | 2025 | Ibsrela |
| Therapeuticsmd, INC. | $36.21 | 2019-2021 | |
| Tris Pharma INC | $35.16 | 2023-2024 | Dyanavel Xr |
| Xeris Pharmaceuticals, INC. | $23.12 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $22.44 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $21.65 | 2025 | Eliquis |
| Ibsa Pharma INC. | $21.02 | 2024 | Tirosint, Licart |
| Seqirus USA INC | $19.10 | 2025 | Flucelvax |
| Sumitomo Pharma America, INC. | $18.83 | 2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $18.16 | 2021 | |
| Axsome Therapeutics, INC. | $17.81 | 2025 | Auvelity |
| Azurity Pharmaceuticals, INC. | $17.77 | 2023 | Edarbi |
| Tactile Systems Technology INC | $17.73 | 2025 | Nimbl, Flexitouch Plus |
| Janssen Pharmaceuticals, INC | $14.94 | 2024 | Xarelto |
| Noven Therapeutics, LLC | $13.75 | 2023 | Xelstrym |
| Antares Pharma, INC. | $13.71 | 2024 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $13.70 | 2024 | Zoryve |
| Esperion Therapeutics, INC. | $12.83 | 2023 | Nexletol |
| Organon LLC | $9.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charla Sperring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.